Malvern Instruments Acquires NanoSight - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Malvern Instruments Acquires NanoSight



Malvern Instruments, a provider of instrumentation for materials and biophysical characterization, has acquired nanoparticle characterization company NanoSight. The acquisition was completed on Sept. 27, 2013.
 
NanoSight has developed and commercialized Nanoparticle Tracking Analysis (NTA). The company’s instrumentation and software enable multi-parameter analysis and characterization of many different types of nanoscale particles. Nanosight’s ability to analyze particle size, concentration, zeta potential, and aggregation, closely aligns with Malvern’s Zetasizer range, extending Malvern’s solutions for those working at the nanoscale. 
 
NanoSight will continue to operate from its current facilities in Amesbury, Wiltshire, UK, under the existing management team.

Source: NanoSight

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
27%
Attracting a skilled workforce
30%
Obtaining/maintaining adequate financing
10%
Regulatory compliance
33%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans

Click here